A comment on "Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was".
作者信息
Herman William H, Kuo Shihchen, Zhang Ping
机构信息
Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
出版信息
Diabetes Obes Metab. 2025 Mar;27(3):1626-1627. doi: 10.1111/dom.16124. Epub 2024 Dec 18.
Abstract
摘要
相似文献
1
A comment on "Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was".关于“二甲双胍在糖尿病预防计划3年试验中的情况：从未实现的成本效益”的评论
Diabetes Obes Metab. 2025 Mar;27(3):1626-1627. doi: 10.1111/dom.16124. Epub 2024 Dec 18.
2
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.肥胖治疗的长期效果、经济后果及其对健康改善影响的系统评价
Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. doi: 10.3310/hta8210.
3
Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.基于微模拟模型的中国 2 型糖尿病患者经二甲双胍治疗控制不佳时，六种 GLP-1RA 的有效性和成本效益分析。
Front Public Health. 2023 Sep 6;11:1201818. doi: 10.3389/fpubh.2023.1201818. eCollection 2023.
4
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial.在美国糖尿病预防计划随机临床试验中，生活方式和二甲双胍干预对2型糖尿病发病率的21年长期影响及效应异质性。
Lancet Diabetes Endocrinol. 2025 Jun;13(6):469-481. doi: 10.1016/S2213-8587(25)00022-1. Epub 2025 Apr 28.
5
Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes.预防2型糖尿病：对生活方式干预计划和二甲双胍用于糖尿病前期（无论是否进行筛查）的成本效益研究的系统评价
BMJ Open. 2017 Nov 15;7(11):e017184. doi: 10.1136/bmjopen-2017-017184.
6
A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.儿童肾移植免疫抑制治疗的临床及成本效益的系统评价与经济学模型
Health Technol Assess. 2006 Dec;10(49):iii-iv, ix-xi, 1-157. doi: 10.3310/hta10490.
7
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.吡格列酮和罗格列酮治疗2型糖尿病的临床疗效和成本效益：系统评价与经济评估
Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. doi: 10.3310/hta8130.
8
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee.妊娠期高血糖筛查：国家筛查委员会快速更新。
Health Technol Assess. 2010 Sep;14(45):1-183. doi: 10.3310/hta14450.
9
Psychological and/or educational interventions for the prevention of depression in children and adolescents.预防儿童和青少年抑郁症的心理和/或教育干预措施。
Cochrane Database Syst Rev. 2004(1):CD003380. doi: 10.1002/14651858.CD003380.pub2.
10
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.依那西普和英夫利昔单抗治疗银屑病关节炎：系统评价与经济学评估
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310.
本文引用的文献
1
Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was.二甲双胍在糖尿病预防计划 3 年试验中的成本效益：从未实现过的成本效益。
Diabetes Obes Metab. 2024 Nov;26(11):5097-5106. doi: 10.1111/dom.15851. Epub 2024 Aug 14.
2
Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained.当资源有限时，针对糖尿病预防计划的目标定位会带来显著的收益。
Acta Diabetol. 2021 Jun;58(6):707-722. doi: 10.1007/s00592-021-01672-3. Epub 2021 Jan 30.
3
Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.生活方式与二甲双胍干预对糖调节受损的超重或肥胖人群进展为糖尿病及恢复至正常糖调节风险的影响。
Diabetes Care. 2017 Dec;40(12):1668-1677. doi: 10.2337/dc17-1116. Epub 2017 Oct 11.
4
Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program.通过基于获益的个性化治疗改善糖尿病预防：糖尿病预防计划的基于风险的重新分析
BMJ. 2015 Feb 19;350:h454. doi: 10.1136/bmj.h454.
5
Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.糖尿病预防依从者的效果和成本效益。
Am J Manag Care. 2013;19(3):194-202.
6
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.生活方式干预或二甲双胍预防糖尿病的 10 年成本效益：DPP/DPPOS 的意向治疗分析。
Diabetes Care. 2012 Apr;35(4):723-30. doi: 10.2337/dc11-1468.
7
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.生活方式干预或二甲双胍在预防糖耐量受损成年人2型糖尿病方面的成本效益。
Ann Intern Med. 2005 Mar 1;142(5):323-32. doi: 10.7326/0003-4819-142-5-200503010-00007.
8
Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.生活方式干预或二甲双胍用于2型糖尿病一级预防的试验内成本效益
Diabetes Care. 2003 Sep;26(9):2518-23. doi: 10.2337/diacare.26.9.2518.
Zotero 插件